Miniatura

Fitxers

s12890-023-02605-2.pdf (1.09 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2023-08-26

Llicència de publicació

cc by (c) Fuset, María Paz et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201908

Days spent on non-invasive ventilation support: can it determine when to initiate VV- ECMO? Observational study in a cohort of Covid-19 patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12890-023-02605-2

Resum

Background The study evaluates the impact of the time between commencing non-invasive ventilation (NIV) support and initiation of venovenous extracorporeal membrane oxygenation (VV-ECMO) in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome (ARDS).Methods Prospective observational study design in an intensive Care Unit (ICU) of a tertiary hospital in Barcelona (Spain). All patients requiring VV-ECMO support due to COVID-19 associated ARDS between March 2020 and January 2022 were analysed. Survival outcome was determined at 90 days after VV-ECMO initiation. Demographic data, comorbidities at ICU admission, RESP (respiratory ECMO survival prediction) score, antiviral and immunomodulatory treatments received, inflammatory biomarkers, the need for vasopressors, the thromboprophylaxis regimen received, and respiratory parameters including the length of intubation previous to ECMO and the length of each NIV support (high-flow nasal cannula, continuous positive airway pressure and bi-level positive airway pressure), were also collated in order to assess risk factors for day-90 mortality. The effect of the time lapse between NIV support and VV-ECMO on survival was evaluated using logistic regression and adjusting the association with all factors that were significant in the univariate analysis.Results Seventy-two patients finally received VV-ECMO support. At 90 days after commencing VV-ECMO 35 patients (48%) had died and 37 patients (52%) were alive. Multivariable analysis showed that at VV-ECMO initiation, age (p = 0.02), lactate (p = 0.001), and days from initiation of NIV support to starting VV-ECMO (p = 0.04) were all associated with day-90 mortality.Conclusions In our small cohort of VV-ECMO patients with COVID-19 associated ARDS, the time spent between initiation of NIV support and VV-ECMO (together with age and lactate) appeared to be a better predictor of mortality than the time between intubation and VV-ECMO.

Matèries

COVID-19, Respiració artificial, Comorbiditat

Matèries (anglès)

COVID-19, Artificial respiration, Comorbidity

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

FUSET, Maria paz, HERNÁNDEZ PLATERO, Lluisa, SABATER RIERA, Joan, GORDILLO BENITEZ, Miguel, PAOLO, Fabio di, CÁRDENAS CAMPOS, Paola, MAISTERRA SANTOS, Krystel, PONS SERRA, María, SASTRE PÉREZ, Paola, GARCÍA ZALOÑA, Alejandro, PUENTES YAÑEZ, Javiera, PÉREZ FERNÁNDEZ, Xosé luis. Days spent on non-invasive ventilation support: can it determine when to initiate VV- ECMO? Observational study in a cohort of Covid-19 patients. _BMC Pulmonary Medicine_. 2023. Vol. 23, núm. 1. [consulta: 25 de febrer de 2026]. ISSN: 1471-2466. [Disponible a: https://hdl.handle.net/2445/201908]

Exportar metadades

JSON - METS

Compartir registre